comparemela.com

Latest Breaking News On - Tom mclain - Page 3 : comparemela.com

Investegate |Renalytix AI PLC Announcements | Renalytix AI PLC: Key new hires to drive commercialization strategy

Investegate | Company News | Corporate, London Stock Exchange, Regulatory News Headlines Renalytix granted 10-year contract by US government

By BFN News | 09:50 AM | Thursday 22 April, 2021 Renalytix AI plc has announced that the United States government has granted the company a 10-year Governmentwide Acquisition Contract (GWAC) to provide KidneyIntelX early-stage kidney disease bioprognostic? testing services. The contract, offered through the General Services Administration (GSA), covers laboratory testing services that can be provided through more than 140 US government departments, agencies and affiliates, including the US Veterans Administration (VA), Department of Defense (DoD) military branches (Army, Navy, Air Force, and Marines), and Indian Health Services (IHS). Effective as of April 15, 2021, the contract has a five-year term with a five-year extension option, and is structured as an Indefinite Delivery, Indefinite Quantity (IDIQ) contract providing for an unlimited quantity of services over the contract term.

Renalytix Commends HHS/CMS on Finalization of MCIT Rule to Provide National Medicare Coverage for FDA Breakthrough Devices and Diagnostics

Home / Top News / Renalytix Commends HHS/CMS on Finalization of MCIT Rule to Provide National Medicare Coverage for FDA Breakthrough Devices and Diagnostics Renalytix Commends HHS/CMS on Finalization of MCIT Rule to Provide National Medicare Coverage for FDA Breakthrough Devices and Diagnostics Creates Pathway for Beneficiary Access to KidneyIntelX for Medicare Beneficiary Kidney Disease Populations NEW YORK, Jan. 13, 2021 (GLOBE NEWSWIRE) The Centers for Medicaid & Medicare (CMS) announced the establishment of the Medicare Coverage of Innovative Technology (MCIT) pathway ( RIN: 0938-AT88), to provide a coverage pathway for Medicare beneficiaries nationwide to have faster access to new, innovative medical devices and diagnostic tests designated under the Breakthrough Device review program and with market authorization by the U.S. Food and Drug Administration (FDA). Under MCIT, national Medicare coverage can become effective on the date of FDA approval or clearance of a breakthr

Investegate |Renalytix AI PLC Announcements | Renalytix AI PLC: Finalization of MCIT rule for coverage pathway

About RenalytixAI RenalytixAI (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company s lead product is KidneyIntelX.com (visit www.kidneyintelx.com ) which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit www.renalytixai.com   Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Examples of these forward-looking statements include statements concerning: the potential for KidneyIntelX to receive regula

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.